Indian Pharmaceuticals major Dr. Reddy's Laboratories (RDY) reported Friday a sharp increase in second-quarter profit, reflecting chiefly a 14% growth in revenues from Global Generics business.
For the second quarter of fiscal 2010, profit more than doubled to US$ 45 million or US$ 0.3 per share from US$ 22 million or US$ 0.1 per share in the previous year. In terms of Indian Rupees, profit was INR 2.17 billion or INR12.8 a share, up from INR1.05 billion or INR 6.2 a share last year. Profit, after adjusting for exceptions in the previous year, grew 79%.
Operating income improved to US$ 53 million or INR2.6 billion from US$ 37 million or INR1.8 billion in the second quarter of fiscal 2009.
Consolidated revenues for the quarter surged 14% to US$ 382 million or INR18.37 billion from US$ 336 million or INR16.15 billion, mainly driven by Global Generics.
Revenues from Global Generics business increased 14% to US$ 264 million from US$ 231 million, attributable to key markets of North America, Russia and India. Revenues from Pharmaceutical Services and Active Ingredients rose 11% to US$ 112 million US$ 100 million in the year-ago period.
Gross margin dipped to year-over-year to 47% from 49%, hurt by one-time inventory provisions of Euro 6 million in betapharm on account of non-moving stocks and US$ 4 million in the U.S. for inventory valuation adjustments of sumatriptan stocks lying with the company. Excluding the one-time items, the adjusted margins for the second quarter of fiscal 2010 stood at 51%.
For the first half of the year, consolidated revenues was INR36.6 billion, up 17% from the past year.
RDY closed Thursday's regular trading hours at $19.70 on the NYSE.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.